AstraZeneca (AZN) Reports Q4 EPS of $1.30

AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.30, $0.83 better than the analyst estimate of $0.47. Revenue for the quarter came in at $5.78 billion versus the consensus estimate of $5.45 billion.

GUIDANCE:

AstraZeneca sees FY2018 EPS of $3.30-$3.50, versus the consensus of $1.62.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance